Daily Brief China: CK Hutchison, Hang Seng Index, SKG Health Technologies, Tianjin Chenxing Technology, Direct Drive Tech, Shenzhen Immunofoco, ATRenew and more

• Last week, CK Hutchison (1 HK) reported a 6.1% and 6.4% lift in 1H26 revenue and underlying net profit (excluding one-off items) to HK$241.6bn and HK$12.6bn. Pretty decent numbers.
• End-July, CKH offloaded its 49% stake in VodafoneThree for US$5.8bn. No mention of the AS Watson IPO in the results or the anaylsts’ call. Reportedly it’s been delayed to 2027.
• The Panama port cessation incurred a HK$496mn hit to EBITDA. CKH has now announced a  Investment Treaty Arbitration against the Panamanian Republic, an entirely separate claim to the contractual arbitration.

• UK Telecom Exit Liquidity Windfall: CK Hutchison’s sudden £4.3 billion (€4.9 billion) cash exit from its 49% stake in VodafoneThree on July 30, 2026, completely reshapes its balance sheet. Confronted with onerous UK CMA behavioural commitments, including an £11.1 billion network upgrade, CK Hutchison opted for immediate asset monetization, generating HK$45.5 billion in cash to defend its Moody’s A2 and Fitch A investment-grade credit ratings.
• Geopolitical Squeeze and Ports Stagnation: The escalating concession dispute in Panama, highlighted by CK Hutchison filing a $1.5 billion (HK$11.7 billion) treaty arbitration on August 20, 2026, represents a broader sovereign risk read-through. This escalating dispute and national security scrutiny have indefinitely delayed the $22.8 billion global ports portfolio sale to BlackRock and MSC, forcing the company to hold onto low-growth, high-capex marine terminals.
• The Watson Valuation Standoff: The long-delayed A.S. Watson IPO remains stalled at a rigid $30 billion target valuation. Because public markets price retail peers at 7x to 9x EBITDA while CK Hutchison demands an 11x to 12x multiple to facilitate a clean exit for its 24.95% minority partner Temasek, the parent company prefers to extract high-margin retail dividends rather than accept an IPO discount.

• Earnings remained a major driver of individual stock moves, creating sharp contrasts beneath an otherwise stronger broader market.
• Option activity increased across the week, while Call participation remained relatively subdued despite the stronger equity backdrop.
• Health Care drew renewed attention as biotech enthusiasm helped lift activity and performance across the sector.

• SKG Health Technologies Co., Ltd. develops smart devices for soothing, recovery, and health management across wearables and home products. It ranked first in China’s smart soothing wearables industry by GMV.
• SKG Health Technologies ranked first globally in smart soothing wearables with 4.6% market share in 2025, holding 1,554 registered patents worldwide.
• Revenue was RMB1,217,540 thousand in 2025, and net profit decreased slightly to RMB131.8 million in the same year.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Government subsidies are the only reason the company has ever shown a profit: While Chenxing reported a paper thin net profit of 0.74 million RMB in 2025, this was entirely propped up by 8.88 million RMB in government subsidies. Stripping this out, the company has consistently been in the red, including a -28.80 million RMB net loss in the first half of 2026.
• Cross-product diversification into SCARA is currently a value-destroying venture: To expand beyond their core parallel robot market, Chenxing entered the SCARA market, where they are bleeding cash. High-speed SCARA gross margins were -125.1% in 2024, -18.3% in 2025, and remained highly negative at -23.1% in the first half of 2026 due to aggressive price discounting against entrenched giants like Inovance and Epson.
• The June 2026 name change back to “Chenxing” was a mandatory legal maneuver to clear copyright liabilities ahead of the HK IPO: Reverting from “Atomrobot” back to “Chenxing Technology” was not an arbitrary rebranding, but a necessary step to mitigate overseas IP litigation risk associated with Japanese cartoonist Osamu Tezuka’s “Astro Boy” (translated as “铁臂阿童木” in Chinese) as they pivot to international markets and list under Chapter 18C.

• Direct Drive Tech Limited is a robotics technology company specializing in direct drive technology, selling robotic actuator modules and robots in China. It seeks a Main Board HKEX listing under.
• Direct Drive Tech ranked 1st in PRC consumer robotic direct drive actuator modules by revenue in 2025 with 61.1% market share. Revenue increased from RMB17.5 million in 2023 to RMB281.7.
• The company incurred operating loss since inception, with net loss of (880,977) RMB’000 in 2025 and net liabilities of (1,347,370) RMB’000 as of June 30, 2026.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• The commercial viability of in vivo CAR-T platforms like Immunofoco’s iMAGIC hinges on the biological trade-offs of using a viral vector. While the mutated MxV glycoprotein (MxV-G-mut) and T-cell targeting module (TCM3) successfully bypass the traditional VSV-G patent thicket and show high specificity in preclinical models (IMV101 and IMV102), the permanent genomic integration of a lentiviral vector carries long-term insertional mutagenesis risks that may limit its use in autoimmune indications compared to transient LNP-mRNA systems like Capstan’s CPTX2309.
• The regulatory feasibility of solid-tumor CAR-T has been proven, but clinical benchmarks remain weak. CARsgen’s NMPA approval of satricabtagene autoleucel (CT041) on June 22, 2026, for third-line gastric cancer established a precedent, but its modest efficacy (median PFS of 3.25 months vs 1.77 months for physician’s choice) leaves a massive commercial gap. Immunofoco is trying to exploit this with its VHH-nanobody-based IMC002, currently in a Phase III trial (NCT07103668), aiming for better safety and durability, but patient recruitment in China’s crowded clinical environment remains a major bottleneck.
• Immunofoco’s financial position is critical, making its recent Hong Kong IPO filing a survival-driven defense. Having raised a cumulative RMB 973 million through its Series C in February 2026 (which valued the company at a post-money RMB 2.075 billion), the company’s updated HKEX filing on August 18, 2026, is essential to fund the expensive Phase III of IMC002 and push IMV101 through clinical trials. Without a successful IPO or a major cross-border out-licensing deal within the next nine to twelve months, the company’s cash runway will be fully depleted.

• Higher memory costs remain the primary storyline in the world of consumer electronics.
• Higher memory costs and supply disruptions have led to price increases from many consumer electronics OEMs. Higher prices for new handsets have negatively impacted demand for new devices but have increased demand in the secondary market, where ATRenew operates.
• ATRenew continues to explore new business lines and service models to increase brand awareness and increase the percentage of customer spending it can capture.